Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Innate Pharma (IPHA) Net Margin (2020 - 2024)

Historic Net Margin for Innate Pharma (IPHA) over the last 5 years, with Q4 2024 value amounting to 596.54%.

  • Innate Pharma's Net Margin fell 5819500.0% to 596.54% in Q4 2024 from the same period last year, while for Jun 2025 it was 77.4%, marking a year-over-year decrease of 723400.0%. This contributed to the annual value of 0.23% for FY2022, which is 294500.0% up from last year.
  • Per Innate Pharma's latest filing, its Net Margin stood at 596.54% for Q4 2024, which was down 5819500.0% from 14.59% recorded in Q4 2023.
  • In the past 5 years, Innate Pharma's Net Margin registered a high of 0.12% during Q4 2022, and its lowest value of 596.54% during Q4 2024.
  • Moreover, its 5-year median value for Net Margin was 112.47% (2020), whereas its average is 219.84%.
  • Its Net Margin has fluctuated over the past 5 years, first soared by 3753600bps in 2022, then tumbled by -5819500bps in 2024.
  • Innate Pharma's Net Margin (Quarter) stood at 112.47% in 2020, then tumbled by -234bps to 375.48% in 2021, then surged by 100bps to 0.12% in 2022, then tumbled by -12374bps to 14.59% in 2023, then tumbled by -3990bps to 596.54% in 2024.
  • Its Net Margin stands at 596.54% for Q4 2024, versus 14.59% for Q4 2023 and 0.12% for Q4 2022.